İsmail SAYGIN, Abdulkadir REİS, Yavuz ÖZORAN, Ümit ÇOBANOĞLU

Benign ve Malign Tiroid Lezyonlarının Ayırımında İmmünhistokimyanın Kullanımı

gibi değişik potansiyel tanısal immünhistokimyasal belirleyicilerin katkısını araştırmak. Gereç ve Yöntem: Bu retrospektif çalışmaya FA, FC, PC ve AN/HN tanısı almış toplam 121 vaka dahil edilmiştir. Vakalar tekrar gözden geçirildikten sonra uygun bloklara immünhistokimyasal işaretleyiciler çalışılmıştır. Lezyonun %10 ve üstünün boyanması pozitif olarak kabul edilmiştir. Ayrıca lezyonların boyanma yoğunluğu üç dereceye ayrılarak (hafif-orta-kuvvetli) yorumlanmıştır. Sonuçlar istatistiksel olarak değerlendirilmiştir. Niteliksel verilerin karşılaştırılmasında Pearson Ki-kare testi kullanılmıştır. Anlamlılık düzeyi p

Diagnostic Use of Immunohistochemical Markers in Benign and Malignant Thyroid Lesions

Objective: The aim of this study is evaluate benign and malignant thyroid lesions and evaluate the contribution of various diagnostic immunohistochemical markers such as CK19, HBME1, CITED1 and Galectin3. Material and Method: This retrospective study includes 121 cases which were diagnosed as FA, FC, PC and AN/HN. Cases were reviewed again and immunohistochemical markers were studied by the suitable paraffin blocks. By the staining of the lesion, 10% and upper levels of expression were accepted as positive. In addition, the intensity of the expression was interpreted in three degrees (mild-moderate-strong). The results were evaluated statistically. Pearson Chi-square test was used to compare qualitative data. Significance level was taken as p

PDF

___

1. De Lellis R. Tumours of the thyroid and parathyroid. Tumors, Pathology and Genetics of Endocrine Organs, WHO Blue Books. Lyon İARC Pres 2004; 50-66.
2. Rosai J. Thyroid gland. In: Rosai J eds. Rosai and Ackerman’s Surgical Pathology. 10th ed. Vol I, Mosby 2011; 496-524
3. Manju L Prasad, Natalia S Pellegata, Ying Huang, et al. Galectin3, fibronectin1, CITED1, HBME1 and cytokeratin19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology 2005;18: 48-57
4. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002; 41: 236-43.
5. Saxen E, Franssila K, Bjarnason O, et al. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand 1978; 86: 483-6.
6. Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME1, Galectin-3, CK19, and CITED1 and Evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 700-8
7. Manju L. Prasad, Natalia S. Pellegata, Richard T. Kloos, et al. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 2004; 14: 169-75.
8. Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of Galectin-3, HBME1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27 in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007; 22: 621-8.
9. Aratake Y, Umeki K, Kiyoyama K. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002; 26: 366-72.
10. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999; 85: 2475-84.
11. Oestreicher-Kedem Y, Halpern M, Roizman P, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004; 26: 960-6.
12. Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules. Histopathology 2002; 40: 80-7.
13. Suh YJ, Moon HJ, Choe JY, et al. the cancer genome atlas validation of ancillary tests for classifying papillary thyroid carcinoma. Int J Thyroidol 2017; 10: 24-35.
14. Dockhorn-Dworniczak B, Frank WW, Schroder S, et al. Patterns of cytoskeletal proteins in human thyroid gland and thyroid carcinoma. Differentiation 1987; 35; 53-71.
15. L. D. R. Thompson, “Update on follicular variant of papillary thyroid carcinoma with an emphasis on new terminology: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features.” Diagnostic Histopathology 2016; 22: 171-8.
16. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma. Mod Pathol 2001; 14: 338-42.
17. Kapran Y, Yavuz E, Giles Y, ve ark. Folliküler kökenli tiroid tümörlerinin tanısında HBME-1 antikorunun yeri. İstanbul Tıp Fakültesi Mecmuası 2000; 63: 62.
18. Rossi ED, Raffaelli M, Mule A, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006; 48: 795-800.
19. Arcolia V, Journe F, Renaud F, et al. Combination of galectin-3, CK19 and HBME1 immunostaining improves the diagnosis of thyroid cancer. Oncology Letters 2017; 14: 4183-9.
20. Teng XD, Wang LJ, Yao HT, et al. Expression of cytokeratin19, galectin-3 and HBME1 in thyroid lesions and their differential diagnoses. Zhonghua Bing Li Xue Za Zhi 2004; 33: 212-6.